IND cleared for SC291, a Hypoimmune-modified, CD19-targeted Allogeneic CAR T Therapy for Patients with B-Cell Malignancies February 1, 2023
Kite To Acquire Tmunity Therapeutics To Pursue Next Generation CAR T-Cell Therapy Advancements In Cancer January 4, 2023
FDA Approves Clinical Trial Application for BCMA CAR-T CT103A for R/R Multiple Myeloma January 4, 2023
FDA Clears IND Application for BCMA CAR-T CB-011 for the Treatment of R/R Multiple Myeloma November 30, 2022
Tessa Therapeutics, Baylor College of Medicine Execute Agreement For Global Commercial Rights to ‘Off-the-Shelf’ CAR-T Platform November 16, 2022
Innovation Passport Designation granted to Biologic CAR T-Cell Therapy Engager ALETA-001 November 16, 2022
Inceptor Bio and Avectas Announce Collaboration to Improve Manufacturing of CAR-T Cell Therapies for the Treatment of Solid Tumors October 19, 2022
Allogene Therapeutics Launches CAR T Together™ Initiative Focused on Accelerating Development and Clinical Trial Recruitment for “Off-The-Shelf” Allogeneic Cell Therapy Investigational Products October 19, 2022
Development of CYAD-101, Allogeneic TIM-based, NKG2D CAR T Candidate for Metastatic Colorectal Cancer (mCRC), to be discontinued October 19, 2022
Autolus Therapeutics Announces Collaboration with Bristol Myers Squibb for Use of Autolus’ Proprietary Safety Switch System October 12, 2022
